{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:33:09Z","timestamp":1792251189029,"version":"4.4.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Venous thromboembolism (VTE) is a leading cause of cardiovascular mortality. The diagnosis of acute VTE is based on complex imaging exams due to the lack of biomarkers. Recent multi-omics based research has contributed to the development of novel biomarkers in cardiovascular diseases. Our aim was to determine whether patients with acute VTE have differences in the metabolomic profile compared to non-acute VTE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This observational trial included 62 patients with clinical suspicion of acute deep vein thrombosis or pulmonary embolism, admitted to the emergency room. There were 50 patients diagnosed with acute VTE and 12 with non-acute VTE conditions and no significant differences were found between the two groups for clinical and demographic characteristics. Metabolomics assays identified and quantified a final number of 91 metabolites in plasma and 55 metabolites in red blood cells (RBCs). Plasma from acute VTE patients expressed tendency to a specific metabolomic signature, with univariate analyses revealing 23 significantly different molecules between acute VTE patients and controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). The most relevant metabolic pathway with the strongest impact on the acute VTE phenotype was\n                      <jats:sc>d<\/jats:sc>\n                      -glutamine and\n                      <jats:sc>d<\/jats:sc>\n                      -glutamate (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001, false discovery rate\u2009=\u20090.06). RBCs revealed a specific metabolomic signature in patients with a confirmed diagnosis of DVT or PE that distinguished them from other acutely diseased patients, represented by 20 significantly higher metabolites and four lower metabolites. Three of those metabolites revealed high performant ROC curves, including adenosine 3\u2032,5\u2032-diphosphate (AUC 0.983), glutathione (AUC 0.923), and adenine (AUC 0.91). Overall, the metabolic pathway most impacting to the differences observed in the RBCs was the purine metabolism (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.000354, false discovery rate\u2009=\u20090.68).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings show that metabolite differences exist between acute VTE and nonacute VTE patients admitted to the ER in the early phases. Three potential biomarkers obtained from RBCs showed high performance for acute VTE diagnosis. Further studies should investigate accessible laboratory methods for the future daily practice usefulness of these metabolites for the early diagnosis of acute VTE in the ER.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-024-04883-8","type":"journal-article","created":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T08:02:09Z","timestamp":1708761729000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Acute venous thromboembolism plasma and red blood cell metabolomic profiling reveals potential new early diagnostic biomarkers: observational clinical study"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3093-0669","authenticated-orcid":false,"given":"Cl\u00e1udia","family":"Febra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Saraiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1tima","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Macedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza Mohammad","family":"Al-Hroub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Harb","family":"Semreen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitor","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Penque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,24]]},"reference":[{"key":"4883_CR1","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1161\/ATVBAHA.114.304488","volume":"34","author":"GE Raskob","year":"2014","unstructured":"Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ, et al. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014;34:2363\u201371.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4883_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","volume":"12","author":"JA Heit","year":"2015","unstructured":"Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12:464\u201374.","journal-title":"Nat Rev Cardiol"},{"key":"4883_CR3","doi-asserted-by":"publisher","first-page":"516","DOI":"10.5694\/mja2.50201","volume":"210","author":"PC Kruger","year":"2019","unstructured":"Kruger PC, Eikelboom JW, Douketis JD, Hankey GJ. Deep vein thrombosis: update on diagnosis and management. Med J Aust. 2019;210:516\u201324.","journal-title":"Med J Aust"},{"key":"4883_CR4","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000000130","volume":"130","author":"SR Kahn","year":"2014","unstructured":"Kahn SR, Comerota AJ, Cushman M, Evans NS, Ginsberg JS, Goldenberg NA, et al. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2014;130:1636\u201361.","journal-title":"Circulation"},{"key":"4883_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41:543\u2013603.","journal-title":"Eur Heart J"},{"key":"4883_CR6","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","volume":"4","author":"TL Ortel","year":"2020","unstructured":"Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4:4693\u2013738.","journal-title":"Blood Adv"},{"key":"4883_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.tcm.2021.06.002","volume":"32","author":"P-M Roy","year":"2022","unstructured":"Roy P-M, Douillet D, Penaloza A. Contemporary management of acute pulmonary embolism. Trends Cardiovasc Med. 2022;32:259\u201368.","journal-title":"Trends Cardiovasc Med"},{"key":"4883_CR8","doi-asserted-by":"crossref","unstructured":"Metabolites | Free Full-Text | Metabolomic Profile in Venous Thromboembolism (VTE) [Internet]. [cited 2023 July 6]. Available from: https:\/\/www.mdpi.com\/2218-1989\/11\/8\/495.","DOI":"10.3390\/metabo11080495"},{"key":"4883_CR9","first-page":"1","volume":"13","author":"R Wawrzyniak","year":"2013","unstructured":"Wawrzyniak R, Garcia Alvarez A, Rup\u00e9rez F, Nu\u00f1o-Ayala M, Garcia A, Ruiz-Cabello J, et al. Metabolomics reveals metabolite changes in acute pulmonary embolism. J Proteome Res. 2013;13:1.","journal-title":"J Proteome Res"},{"key":"4883_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.thromres.2019.03.011","volume":"177","author":"K Maekawa","year":"2019","unstructured":"Maekawa K, Sugita C, Yamashita A, Moriguchi-Goto S, Furukoji E, Sakae T, et al. Higher lactate and purine metabolite levels in erythrocyte-rich fresh venous thrombus: potential markers for early deep vein thrombosis. Thromb Res. 2019;177:136\u201344.","journal-title":"Thromb Res"},{"key":"4883_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/jssc.201500982","volume":"39","author":"M Al Za\u2019abi","year":"2016","unstructured":"Al Za\u2019abi M, Ali BH, ALOthman ZA, Ali I. Analyses of acute kidney injury biomarkers by ultra-high performance liquid chromatography with mass spectrometry. J Sep Sci. 2016;39:69\u201382.","journal-title":"J Sep Sci"},{"key":"4883_CR12","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1111\/trf.15467","volume":"59","author":"S Gehrke","year":"2019","unstructured":"Gehrke S, Shah N, Gamboni F, Kamyszek R, Srinivasan AJ, Gray A, et al. Metabolic impact of red blood cell exchange with rejuvenated red blood cells in sickle cell patients. Transfusion (Paris). 2019;59:3102\u201312.","journal-title":"Transfusion (Paris)"},{"key":"4883_CR13","doi-asserted-by":"publisher","first-page":"e2000178","DOI":"10.1002\/mnfr.202000178","volume":"64","author":"P Hern\u00e1ndez-Alonso","year":"2020","unstructured":"Hern\u00e1ndez-Alonso P, Becerra-Tom\u00e1s N, Papandreou C, Bull\u00f3 M, Guasch-Ferr\u00e9 M, Toledo E, et al. Plasma metabolomics profiles were associated with the amount and source of protein intake: a metabolomics approach within the PREDIMED study. Mol Nutr Food Res. 2020;64:e2000178.","journal-title":"Mol Nutr Food Res"},{"key":"4883_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s11306-016-1015-8","volume":"12","author":"R Wehrens","year":"2016","unstructured":"Wehrens R, Hageman JA, van Eeuwijk F, Kooke R, Flood PJ, Wijnker E, et al. Improved batch correction in untargeted MS-based metabolomics. Metabolomics. 2016;12:88.","journal-title":"Metabolomics"},{"key":"4883_CR15","doi-asserted-by":"publisher","first-page":"W652","DOI":"10.1093\/nar\/gkp356","volume":"37","author":"J Xia","year":"2009","unstructured":"Xia J, Psychogios N, Young N, Wishart DS. MetaboAnalyst: a web server for metabolomic data analysis and interpretation. Nucl Acids Res. 2009;37:W652\u201360.","journal-title":"Nucl Acids Res"},{"key":"4883_CR16","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/s41596-022-00710-w","volume":"17","author":"Z Pang","year":"2022","unstructured":"Pang Z, Zhou G, Ewald J, Chang L, Hacariz O, Basu N, et al. Using MetaboAnalyst 5.0 for LC\u2013HRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics data. Nat Protoc. 2022;17:1735\u201361.","journal-title":"Nat Protoc"},{"key":"4883_CR17","doi-asserted-by":"publisher","unstructured":"Clinical Metabolomic Landscape of Cardiovascular Physiology and Disease [Internet]. [cited 2023 Dec 27]. Available from: https:\/\/doi.org\/10.1161\/JAHA.122.027725.","DOI":"10.1161\/JAHA.122.027725"},{"key":"4883_CR18","unstructured":"Eriksson L, Byrne T, Johansson E, Trygg J, Vikstr\u00f6m C. Multi- and Megavariate Data Analysis Basic Principles and Applications. Umetrics Academy; 2013."},{"key":"4883_CR19","doi-asserted-by":"publisher","unstructured":"Xia J. Computational Strategies for Biological Interpretation of Metabolomics Data. In: Sussulini A, editor. Metabolomics Fundam Clin Appl [Internet]. Cham: Springer International Publishing; 2017 [cited 2023 Dec 27]. p. 191\u2013206. Available from: https:\/\/doi.org\/10.1007\/978-3-319-47656-8_8.","DOI":"10.1007\/978-3-319-47656-8_8"},{"key":"4883_CR20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc Ser B Methodol. 1996;58:267\u201388.","journal-title":"J R Stat Soc Ser B Methodol"},{"key":"4883_CR21","unstructured":"Human Metabolome Database [Internet]. [cited 2023 Aug 9]. Available from: https:\/\/hmdb.ca\/."},{"key":"4883_CR22","doi-asserted-by":"publisher","unstructured":"Clinical Metabolomic Landscape of Cardiovascular Physiology and Disease [Internet]. [cited 2023 Sep 15]. Available from: https:\/\/doi.org\/10.1161\/JAHA.122.027725.","DOI":"10.1161\/JAHA.122.027725"},{"key":"4883_CR23","doi-asserted-by":"publisher","first-page":"597546","DOI":"10.3389\/fcvm.2020.597546","volume":"7","author":"J Zhao","year":"2020","unstructured":"Zhao J, Yang S, Jing R, Jin H, Hu Y, Wang J, et al. Plasma metabolomic profiles differentiate patients with dilated cardiomyopathy and ischemic cardiomyopathy. Front Cardiovasc Med. 2020;7:597546.","journal-title":"Front Cardiovasc Med"},{"key":"4883_CR24","doi-asserted-by":"publisher","first-page":"747","DOI":"10.5551\/jat.RV17036","volume":"26","author":"M Iida","year":"2019","unstructured":"Iida M, Harada S, Takebayashi T. Application of metabolomics to epidemiological studies of atherosclerosis and cardiovascular disease. J Atheroscler Thromb. 2019;26:747\u201357.","journal-title":"J Atheroscler Thromb"},{"key":"4883_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/jth.14360","volume":"17","author":"JW Weisel","year":"2019","unstructured":"Weisel JW, Litvinov RI. Red blood cells: the forgotten player in hemostasis and thrombosis. J Thromb Haemost JTH. 2019;17:271\u201382.","journal-title":"J Thromb Haemost JTH"},{"key":"4883_CR26","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2015-03-636761","volume":"126","author":"H Deguchi","year":"2015","unstructured":"Deguchi H, Banerjee Y, Trauger S, Siuzdak G, Kalisiak E, Fern\u00e1ndez JA, et al. Acylcarnitines are anticoagulants that inhibit factor Xa and are reduced in venous thrombosis, based on metabolomics data. Blood. 2015;126:1595\u2013600.","journal-title":"Blood"},{"key":"4883_CR27","doi-asserted-by":"publisher","first-page":"e010317","DOI":"10.1161\/JAHA.118.010317","volume":"7","author":"X Jiang","year":"2018","unstructured":"Jiang X, Zeleznik OA, Lindstr\u00f6m S, Lasky-Su J, Hagan K, Clish CB, et al. Metabolites associated with the risk of incident venous thromboembolism: a metabolomic analysis. J Am Heart Assoc Cardiovasc Cerebrovasc Dis. 2018;7:e010317.","journal-title":"J Am Heart Assoc Cardiovasc Cerebrovasc Dis"},{"key":"4883_CR28","doi-asserted-by":"crossref","unstructured":"Li S, Gao D, Jiang Y. Function, Detection and Alteration of Acylcarnitine Metabolism in Hepatocellular Carcinoma. Metabolites [Internet]. 2019 [cited 2023 Sep 21];9. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6410233\/.","DOI":"10.3390\/metabo9020036"},{"key":"4883_CR29","doi-asserted-by":"publisher","unstructured":"Gillespie AH, Doctor A. Red Blood Cell Contribution to Hemostasis. Front Pediatr [Internet]. 2021 [cited 2023 Aug 1];9. Available from: https:\/\/doi.org\/10.3389\/fped.2021.629824","DOI":"10.3389\/fped.2021.629824"},{"key":"4883_CR30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/jth.14360","volume":"17","author":"JW Weisel","year":"2019","unstructured":"Weisel JW, Litvinov RI. Red blood cells: the forgotten player in hemostasis and thrombosis. J Thromb Haemost. 2019;17:271\u201382.","journal-title":"J Thromb Haemost"},{"key":"4883_CR31","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3390\/metabo13070793","volume":"13","author":"A D\u2019Alessandro","year":"2023","unstructured":"D\u2019Alessandro A, Anastasiadi AT, Tzounakas VL, Nemkov T, Reisz JA, Kriebardis AG, et al. Red blood cell metabolism in vivo and in vitro. Metabolites. 2023;13:793.","journal-title":"Metabolites"},{"key":"4883_CR32","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/14789450.2017.1291347","volume":"14","author":"A D\u2019Alessandro","year":"2017","unstructured":"D\u2019Alessandro A, Zolla L. Proteomic analysis of red blood cells and the potential for the clinic: what have we learned so far? Expert Rev Proteomics. 2017;14:243\u201352.","journal-title":"Expert Rev Proteomics"},{"key":"4883_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1006\/abio.1998.2800","volume":"264","author":"E-S Lin","year":"1998","unstructured":"Lin E-S, Yang Y-S. Colorimetric determination of the purity of 3\u2032-phospho adenosine 5\u2032-phosphosulfate and natural abundance of 3\u2032-phospho adenosine 5\u2032-phosphate at picomole quantities. Anal Biochem. 1998;264:111\u20137.","journal-title":"Anal Biochem"},{"key":"4883_CR34","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1042\/BJ20111057","volume":"443","author":"E Toledano","year":"2012","unstructured":"Toledano E, Ogryzko V, Danchin A, Ladant D, Mechold U. 3\u2032\u20135\u2032 Phosphoadenosine phosphate is an inhibitor of PARP-1 and a potential mediator of the lithium-dependent inhibition of PARP-1 in vivo. Biochem J. 2012;443:485\u201390.","journal-title":"Biochem J"},{"key":"4883_CR35","first-page":"404","volume":"11","author":"CD Klaassen","year":"1997","unstructured":"Klaassen CD, Boles JW. Sulfation and sulfotransferases 5: the importance of 3\u2032-phosphoadenosine 5\u2032-phosphosulfate (PAPS) in the regulation of sulfation. FASEB J Off Publ Fed Am Soc Exp Biol. 1997;11:404\u201318.","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"4883_CR36","doi-asserted-by":"publisher","first-page":"24979","DOI":"10.1074\/jbc.273.39.24979","volume":"273","author":"U Lindahl","year":"1998","unstructured":"Lindahl U, Kusche-Gullberg M, Kjell\u00e9n L. Regulated diversity of heparan sulfate *. J Biol Chem. 1998;273:24979\u201382.","journal-title":"J Biol Chem"},{"key":"4883_CR37","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1042\/BJ20040762","volume":"381","author":"AM Vogt","year":"2004","unstructured":"Vogt AM, Winter G, Wahlgren M, Spillmann D. Heparan sulphate identified on human erythrocytes: a plasmodium falciparum receptor. Biochem J. 2004;381:593\u20137.","journal-title":"Biochem J"},{"key":"4883_CR38","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4236\/abb.2022.132004","volume":"13","author":"TM Alkhamis","year":"2022","unstructured":"Alkhamis TM, Alma\u2019atah BM. Evaluation of red blood cell contribution to platelet activation in the bulk applying red blood cell\u2014platelet thrombus as a point source model. Adv Biosci Biotechnol. 2022;13:92\u2013111.","journal-title":"Adv Biosci Biotechnol"},{"key":"4883_CR39","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1111\/j.1538-7836.2005.01489.x","volume":"3","author":"S Heptinstall","year":"2005","unstructured":"Heptinstall S, Johnson A, Glenn JR, White AE. Adenine nucleotide metabolism in human blood\u2014important roles for leukocytes and erythrocytes. J Thromb Haemost. 2005;3:2331\u20139.","journal-title":"J Thromb Haemost"},{"key":"4883_CR40","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1055\/s-0037-1616220","volume":"86","author":"C Gachet","year":"2001","unstructured":"Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost. 2001;86:222\u201332.","journal-title":"Thromb Haemost"},{"key":"4883_CR41","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1023\/B:CARD.0000015862.62649.c8","volume":"17","author":"V Chopra","year":"2003","unstructured":"Chopra V, Marmur JD, Cavusoglu E. The role of clopidogrel in the management of patients with ischemic heart disease. Cardiovasc Drugs Ther. 2003;17:467\u201377.","journal-title":"Cardiovasc Drugs Ther"},{"key":"4883_CR42","first-page":"1","volume":"2023","author":"M Mikdar","year":"2023","unstructured":"Mikdar M, Serra M, Colin E, Duval R, Gauthier E-F, Lamarre Y, et al. Adenosine signaling inhibits erythropoiesis and promotes myeloid differentiation. Haematologica. 2023;2023:1.","journal-title":"Haematologica"},{"key":"4883_CR43","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/jth.13937","volume":"16","author":"OA Zeleznik","year":"2018","unstructured":"Zeleznik OA, Poole EM, Lindstrom S, Kraft P, Van Hylckama VA, Lasky-Su JA, et al. Metabolomic analysis of 92 pulmonary embolism patients from a nested case\u2013control study identifies metabolites associated with adverse clinical outcomes. J Thromb Haemost. 2018;16:500\u20137.","journal-title":"J Thromb Haemost"},{"key":"4883_CR44","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.ejvs.2018.01.027","volume":"55","author":"Y Sung","year":"2018","unstructured":"Sung Y, Spagou K, Kafeza M, Kyriakides M, Dharmarajah B, Shalhoub J, et al. Deep vein thrombosis exhibits characteristic serum and vein wall metabolic phenotypes in the inferior vena cava ligation mouse model. Eur J Vasc Endovasc Surg. 2018;55:703\u201313.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"4883_CR45","first-page":"176","volume":"11","author":"FS T\u00fcrker","year":"2021","unstructured":"T\u00fcrker FS, Malbora A, Erisir M. Oxidative status and antioxidant enzyme levels in deep venous thrombosis patients. Am J Cardiovasc Dis. 2021;11:176\u201383.","journal-title":"Am J Cardiovasc Dis"},{"key":"4883_CR46","doi-asserted-by":"publisher","first-page":"769","DOI":"10.7754\/Clin.Lab.2015.141106","volume":"61","author":"G Aykal","year":"2015","unstructured":"Aykal G, G\u00fcven R, Ye\u011fin A, Ellida\u011f HY, Bayindir A, Yilmaz N. The diagnostic value of oxidative\/antioxidative balance parameters in venous thromboembolism. Clin Lab. 2015;61:769\u201375.","journal-title":"Clin Lab"},{"key":"4883_CR47","doi-asserted-by":"publisher","first-page":"393","DOI":"10.5114\/aoms.2019.83292","volume":"15","author":"P Poredo\u0161","year":"2019","unstructured":"Poredo\u0161 P, Spirkoska A, Je\u017eovnik MK. In patients with superficial vein thrombosis the inflammatory response is increased and related to the recanalization rate. Arch Med Sci AMS. 2019;15:393\u2013401.","journal-title":"Arch Med Sci AMS"},{"key":"4883_CR48","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.cardiores.2004.06.020","volume":"64","author":"BR Clapp","year":"2004","unstructured":"Clapp BR, Hingorani AD, Kharbanda RK, Mohamed-Ali V, Stephens JW, Vallance P, et al. Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress. Cardiovasc Res. 2004;64:172\u20138.","journal-title":"Cardiovasc Res"},{"key":"4883_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/eurheartj\/ehi041","volume":"26","author":"C Jerjes-Sanchez","year":"2005","unstructured":"Jerjes-Sanchez C. Venous and arterial thrombosis: a continuous spectrum of the same disease? Eur Heart J. 2005;26:3\u20134.","journal-title":"Eur Heart J"},{"key":"4883_CR50","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s11306-013-0595-9","volume":"10","author":"CM Laborde","year":"2014","unstructured":"Laborde CM, Mourino-Alvarez L, Posada-Ayala M, Alvarez-Llamas G, Serranillos-Reus MG, Moreu J, et al. Plasma metabolomics reveals a potential panel of biomarkers for early diagnosis in acute coronary syndrome. Metabolomics. 2014;10:414\u201324.","journal-title":"Metabolomics"},{"key":"4883_CR51","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3390\/metabo11100685","volume":"11","author":"A Surendran","year":"2021","unstructured":"Surendran A, Atefi N, Zhang H, Aliani M, Ravandi A. Defining acute coronary syndrome through metabolomics. Metabolites. 2021;11:685.","journal-title":"Metabolites"},{"key":"4883_CR52","first-page":"3862","volume":"22","author":"Y Liu","year":"2020","unstructured":"Liu Y, Li Y, Zhang T, Zhao H, Fan S, Cai X, et al. Analysis of biomarkers and metabolic pathways in patients with unstable angina based on ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry. Mol Med Rep. 2020;22:3862\u201372.","journal-title":"Mol Med Rep"},{"key":"4883_CR53","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.jacc.2016.06.044","volume":"68","author":"Y Fan","year":"2016","unstructured":"Fan Y, Li Y, Chen Y, Zhao Y-J, Liu L-W, Li J, et al. Comprehensive metabolomic characterization of coronary artery diseases. J Am Coll Cardiol. 2016;68:1281\u201393.","journal-title":"J Am Coll Cardiol"},{"key":"4883_CR54","doi-asserted-by":"publisher","unstructured":"Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years [Internet]. [cited 2023 Sep 20]. Available from: https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.13643.","DOI":"10.1161\/HYPERTENSIONAHA.119.13643"},{"key":"4883_CR55","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1080\/15257770.2020.1730891","volume":"39","author":"LP Jordheim","year":"2020","unstructured":"Jordheim LP, Peters GJ. Recent updates on purine and pyrimidine metabolism in physiological and pathological settings. Nucl Nucl Nucl Acids. 2020;39:1273\u201380.","journal-title":"Nucl Nucl Nucl Acids"},{"key":"4883_CR56","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.amjmed.2005.03.043","volume":"118","author":"JF Baker","year":"2005","unstructured":"Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: Recent developments, and where do they leave us? Am J Med. 2005;118:816\u201326.","journal-title":"Am J Med"},{"key":"4883_CR57","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/jth.15139","volume":"19","author":"L De Lucchi","year":"2021","unstructured":"De Lucchi L, Nardin C, Sponchiado A, Raggi D, Faggin E, Martini E, et al. Serum uric acid levels and the risk of recurrent venous thromboembolism. J Thromb Haemost. 2021;19:194\u2013201.","journal-title":"J Thromb Haemost"},{"key":"4883_CR58","doi-asserted-by":"crossref","unstructured":"Weng H, Li H, Zhang Z, Zhang Y, Xi L, Zhang D, et al. Association between uric acid and risk of venous thromboembolism in East Asian populations: a cohort and Mendelian randomization study. Lancet Reg Health\u2014West Pac [Internet]. 2023 [cited 2023 Sep 20];39. Available from: https:\/\/www.thelancet.com\/journals\/lanwpc\/article\/PIIS2666-6065(23)00166-9\/fulltext.","DOI":"10.1016\/j.lanwpc.2023.100848"},{"key":"4883_CR59","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.numecd.2019.06.005","volume":"29","author":"X Liu","year":"2019","unstructured":"Liu X, Zheng Y, Guasch-Ferr\u00e9 M, Ruiz-Canela M, Toledo E, Clish C, et al. High plasma glutamate and low glutamine-to-glutamate ratio are associated with type 2 diabetes: case-cohort study within the PREDIMED trial. Nutr Metab Cardiovasc Dis NMCD. 2019;29:1040\u20139.","journal-title":"Nutr Metab Cardiovasc Dis NMCD"},{"key":"4883_CR60","doi-asserted-by":"publisher","unstructured":"Metabolites of Glutamate Metabolism Are Associated With Incident Cardiovascular Events in the PREDIMED PREvenci\u00f3n con DIeta MEDiterr\u00e1nea (PREDIMED) Trial [Internet]. [cited 2023 Sep 21]. Available from: https:\/\/doi.org\/10.1161\/JAHA.116.003755.","DOI":"10.1161\/JAHA.116.003755"},{"key":"4883_CR61","first-page":"81","volume":"5","author":"MA Za\u2019abi","year":"2023","unstructured":"Za\u2019abi MA, Ali BH, Ali I. Advances in the methodologies for the analysis of acute kidney injury biomarkers. Recent Pat Biomark. 2023;5:81\u201392.","journal-title":"Recent Pat Biomark"},{"key":"4883_CR62","doi-asserted-by":"publisher","first-page":"100172","DOI":"10.1016\/j.rechem.2021.100172","volume":"3","author":"RL Jayaraj","year":"2021","unstructured":"Jayaraj RL, Narchi H, Subramanian R, Yuvaraju P. Development and validation of LC\u2013MS\/MS method for quantification of ATP, ADP and AMP in dried blood spot, liver and brain of neonate mice pups. Results Chem. 2021;3:100172.","journal-title":"Results Chem"},{"key":"4883_CR63","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.talanta.2018.10.003","volume":"193","author":"M Cortese","year":"2019","unstructured":"Cortese M, Delporte C, Dufour D, Noyon C, Chaumont M, De Becker B, et al. Validation of a LC\/MSMS method for simultaneous quantification of 9 nucleotides in biological matrices. Talanta. 2019;193:206\u201314.","journal-title":"Talanta"},{"key":"4883_CR64","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1039\/C5AN00345H","volume":"140","author":"L Hakuna","year":"2015","unstructured":"Hakuna L, Doughan B, Escobedo JO, Strongin RM. A simple assay for glutathione in whole blood. Analyst. 2015;140:3339\u201342.","journal-title":"Analyst"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-04883-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-04883-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-04883-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T14:07:52Z","timestamp":1731420472000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-04883-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,24]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4883"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-04883-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3507783\/v1","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,24]]},"assertion":[{"value":"28 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical trial part was approved by the Research Committee of the Hospital Beatriz Angelo and the Ethical Commission of INSA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study has not been published before, and this publication has been approved by all authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"200"}}